PortfoliosLab logoPortfoliosLab logo
ATAI vs. XTNT
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ATAI vs. XTNT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Atai Life Sciences N.V. (ATAI) and Xtant Medical Holdings, Inc. (XTNT). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ATAI vs. XTNT - Yearly Performance Comparison


2026 (YTD)20252024202320222021
ATAI
Atai Life Sciences N.V.
-9.54%207.52%-5.67%-46.99%-65.14%-60.77%
XTNT
Xtant Medical Holdings, Inc.
-32.13%76.98%-60.80%71.21%17.86%-65.43%

Fundamentals

EPS

ATAI:

-$2.72

XTNT:

$0.09

PS Ratio

ATAI:

219.71

XTNT:

0.39

Total Revenue (TTM)

ATAI:

$4.09M

XTNT:

$133.93M

Gross Profit (TTM)

ATAI:

$3.08M

XTNT:

$84.27M

EBITDA (TTM)

ATAI:

-$113.05M

XTNT:

$22.15M

Returns By Period

In the year-to-date period, ATAI achieves a -9.54% return, which is significantly higher than XTNT's -32.13% return.


ATAI

1D
4.52%
1M
0.54%
YTD
-9.54%
6M
-28.85%
1Y
198.39%
3Y*
26.91%
5Y*
10Y*

XTNT

1D
-4.64%
1M
-6.88%
YTD
-32.13%
6M
-17.68%
1Y
13.19%
3Y*
-5.85%
5Y*
-25.45%
10Y*
-33.37%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ATAI vs. XTNT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ATAI
ATAI Risk / Return Rank: 8888
Overall Rank
ATAI Sharpe Ratio Rank: 9393
Sharpe Ratio Rank
ATAI Sortino Ratio Rank: 9191
Sortino Ratio Rank
ATAI Omega Ratio Rank: 8787
Omega Ratio Rank
ATAI Calmar Ratio Rank: 8888
Calmar Ratio Rank
ATAI Martin Ratio Rank: 8282
Martin Ratio Rank

XTNT
XTNT Risk / Return Rank: 4848
Overall Rank
XTNT Sharpe Ratio Rank: 4747
Sharpe Ratio Rank
XTNT Sortino Ratio Rank: 5050
Sortino Ratio Rank
XTNT Omega Ratio Rank: 4747
Omega Ratio Rank
XTNT Calmar Ratio Rank: 4848
Calmar Ratio Rank
XTNT Martin Ratio Rank: 4747
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ATAI vs. XTNT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Atai Life Sciences N.V. (ATAI) and Xtant Medical Holdings, Inc. (XTNT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ATAIXTNTDifference

Sharpe ratio

Return per unit of total volatility

2.35

0.20

+2.16

Sortino ratio

Return per unit of downside risk

2.97

0.83

+2.14

Omega ratio

Gain probability vs. loss probability

1.36

1.09

+0.27

Calmar ratio

Return relative to maximum drawdown

3.58

0.31

+3.27

Martin ratio

Return relative to average drawdown

6.67

0.61

+6.06

ATAI vs. XTNT - Sharpe Ratio Comparison

The current ATAI Sharpe Ratio is 2.35, which is higher than the XTNT Sharpe Ratio of 0.20. The chart below compares the historical Sharpe Ratios of ATAI and XTNT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ATAIXTNTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.35

0.20

+2.16

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.34

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.29

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.35

-0.30

-0.05

Correlation

The correlation between ATAI and XTNT is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

ATAI vs. XTNT - Dividend Comparison

Neither ATAI nor XTNT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ATAI vs. XTNT - Drawdown Comparison

The maximum ATAI drawdown since its inception was -94.77%, roughly equal to the maximum XTNT drawdown of -99.17%. Use the drawdown chart below to compare losses from any high point for ATAI and XTNT.


Loading graphics...

Drawdown Indicators


ATAIXTNTDifference

Max Drawdown

Largest peak-to-trough decline

-94.77%

-99.17%

+4.40%

Max Drawdown (1Y)

Largest decline over 1 year

-48.06%

-42.16%

-5.90%

Max Drawdown (5Y)

Largest decline over 5 years

-85.75%

Max Drawdown (10Y)

Largest decline over 10 years

-98.84%

Current Drawdown

Current decline from peak

-81.40%

-98.74%

+17.34%

Average Drawdown

Average peak-to-trough decline

-79.80%

-88.61%

+8.81%

Ulcer Index

Depth and duration of drawdowns from previous peaks

25.79%

21.49%

+4.30%

Volatility

ATAI vs. XTNT - Volatility Comparison

Atai Life Sciences N.V. (ATAI) has a higher volatility of 21.20% compared to Xtant Medical Holdings, Inc. (XTNT) at 15.23%. This indicates that ATAI's price experiences larger fluctuations and is considered to be riskier than XTNT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ATAIXTNTDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.20%

15.23%

+5.97%

Volatility (6M)

Calculated over the trailing 6-month period

53.28%

42.78%

+10.50%

Volatility (1Y)

Calculated over the trailing 1-year period

85.32%

67.76%

+17.56%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

84.10%

74.22%

+9.88%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

84.10%

113.62%

-29.52%

Financials

ATAI vs. XTNT - Financials Comparison

This section allows you to compare key financial metrics between Atai Life Sciences N.V. and Xtant Medical Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00M20.00M30.00M40.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
1.07M
32.36M
(ATAI) Total Revenue
(XTNT) Total Revenue
Values in USD except per share items